CD101 and central nervous system cancer: To further probe the expression pattern of CD101 in glioma, we performed subgroup analyses by stratifying patients with disparate clinical characteristics, including WHO grade, histological type, age, IDH status, 1p/19q codeletion, and primary therapy outcome.